Dr. Wolchok Explains the Future of Ipilimumab
Jedd D. Wolchok, MD, PhD from Memorial Sloan-Kettering Cancer Center explains the future of ipilimumab.
Dr. Wolchok says that, in general, ipilimumab releases a breaking mechanism on the immune system. He says it's versatile in that it could have activity in diseases other than melanoma because it doesn't specifically release an immune response to melanoma. It does release an immune response to melanoma, but there are ongoing studies using ipilimumab in prostate cancer and there have been smaller experiences in ovary cancer and kidney cancer. This brings up the possibility that it could be applied in other disease settings.